3-氨基环戊烷羧酸盐酸盐 | 1203306-05-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基环戊烷羧酸盐酸盐
• 英文名称: cis-3-aminocyclopentane carboxylic acid hydrochloride
• 英文别名: 3-Aminocyclopentanecarboxylic acid hydrochloride；3-aminocyclopentane-1-carboxylic acid;hydrochloride
• CAS: 1203306-05-1；19042-35-4
• 化学式: C₆H₁₁NO₂*ClH
• mdl: MFCD11656836
• 分子量: 165.62
• InChiKey: YJRMNPPUVLZEIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.31
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  63.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-guanidino-4-(3-aminocyclopentyl)thiazole 、 3-氨基环戊烷羧酸盐酸盐 、 N-乙氧羰基邻苯二甲酰亚胺 在 sodium carbonate 作用下， 以 水 为溶剂， 生成 3-phthalimidocyclopentane carboxylic acid
  参考文献：
  名称：

  Guanidine derivatives and pharmaceutical compositions containing them

  摘要：

  瓜尼啉衍生物是组胺H-2拮抗剂，可以抑制胃酸分泌。这些衍生物的化学式为：##STR1## 其中X是氧或硫；Y是氮或一个CH基团；n为1、2、3或4；m为0或1；R.sup.1是，例如，氢或1-6碳原子的烷基；R.sup.2是，例如，##STR2## 具有瓜尼啉基和环烷基取代基，直接连接到杂环环上。

  公开号：

  US04342765A1

文献信息

• [EN] NOVEL OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS INÉDITS D'OXADIAZOLE
  申请人：ABBOTT LAB

  公开号：WO2011071570A1

  公开（公告）日：2011-06-16

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  新型噁二唑化合物，含有这种化合物的药物组合物以及将这些化合物或组合物用作治疗与调节S1P家族G蛋白偶联受体活性相关的疾病的激动剂或拮抗剂的用途被披露，特别是通过提供有益的免疫抑制作用。
• [EN] TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER<br/>[FR] DÉRIVÉS DE TRIAZOLO[4,5-D]PYRIMIDINE POUR LE TRAITEMENT DE MALADIES TELLES QUE LE CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2014135244A1

  公开（公告）日：2014-09-12

  Compounds of the formula I, in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

  式I的化合物，其中R1和R2具有权利要求1中指示的含义，是GCN2的抑制剂，可用于治疗癌症。
• METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF
  申请人：ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

  公开号：US20160375131A1

  公开（公告）日：2016-12-29

  Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction.

  本文提供了一种有理设计尼古丁半抗原的方法。更具体地，本文提供了一种设计、选择和合成尼古丁半抗原和尼古丁半抗原共轭物的方法。本文还提供了新型尼古丁半抗原以及利用尼古丁半抗原治疗尼古丁成瘾的方法。
• Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use
  申请人：Greig Iain Robert

  公开号：US20110172189A1

  公开（公告）日：2011-07-14

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).

  本发明涉及治疗化合物领域，更具体地涉及以下公式的某些芳基-苯基-磺酰胺基环烷化合物（统称为“APSAC化合物”）。本发明还涉及包含这种化合物的制药组合物以及在体内外使用这种化合物和组合物治疗炎症、关节破坏和/或骨质流失等问题，治疗由免疫系统过度和/或不适当和/或持久活化引起的疾病，如类风湿性关节炎、牛皮癣、银屑病性关节炎、慢性阻塞性肺疾病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等炎症和自身免疫性疾病，以及与骨质流失相关的疾病，如类风湿性关节炎、骨质疏松症、癌症相关骨病、帕吉特病等，以及癌症，如血液系统恶性肿瘤、实体瘤等。公式（I）。
• Novel Oxadiazole Compounds
  申请人：Cusack Kevin P.

  公开号：US20110207704A1

  公开（公告）日：2011-08-25

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  本发明涉及新型噁二唑类化合物、含有该类化合物的制药组合物，以及将这些化合物或组合物作为S1P家族G蛋白偶联受体的激动剂或拮抗剂，用于治疗与S1P家族受体活性调节相关的疾病，特别是通过提供有益的免疫抑制作用。